Department of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.
Department of Biostatistics, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA, USA.
Ann Surg Oncol. 2019 Aug;26(8):2327-2335. doi: 10.1245/s10434-019-07380-1. Epub 2019 Apr 29.
With reductions in public funding, alternate research funding is essential to surgical oncologists (SOs). We aimed to examine current trends in industry funding of SOs.
Society of Surgical Oncology surgeons were identified and matched with board certification and years in practice. Departmental and hospital data were evaluated, and industry payments from 2013 to 2017 were matched with the Open Payment Data.
Of the 1670 SOs identified, 922 (55%) had academic positions: 588 (64%) males and 334 (36%) females. Between 2013 and 2017, research payments totaling $46,596,706 were made to 162 SOs (17.5%): $40,774,716 (87%) for research related to drugs and clinical trials, compared with $5,194,199 (11%) for surgical devices (p = 0.018). Funding correlated with academic leadership and years in practice (p = 0.0001 and p = 0.0037). Massachusetts ($9,060,976), Texas ($7,656,228), and New York ($4,210,864) received the most funding, whereas Utah ($1,533,166/SO), Massachusetts ($1,294,425/SO), and Oregon ($1,241,702/SO) received the highest average payments per SO. The majority of funding was from Novartis ($16,045,608), Amgen ($6,810,832), and Merck ($3,758,299), for an oncolytic vaccine (talimogene laherparepvec, $5,939,007), a BRAF inhibitor (dabrafenib, $5,727,309), and a KIT inhibitor (imatinib, $4,323,586). Male SOs received funding more frequently than females (120/588 [20%] vs. 42/334 [12.6%]; p = 0.0027). Males also received more general payments (travel/lodging, food/beverage, consulting/speaker fees): $48,830 vs. $11,867 per male and female, respectively (p = 0.0001).
The majority of industry research payments to SOs are related to novel pharmaceuticals, which highlights the expanding influence SOs play in systemic therapies. Industry payments are influenced by location, gender, and academic leadership.
随着公共资金的减少，外科肿瘤学家需要寻找替代的研究资金。我们旨在研究目前行业对外科肿瘤学家的资助趋势。
确定外科肿瘤学会的外科医生，并与董事会认证和从业年限相匹配。评估部门和医院的数据，并将 2013 年至 2017 年的行业支付与公开支付数据相匹配。
在确定的 1670 名外科肿瘤学家中，有 922 名（55%）具有学术职位：588 名男性（64%）和 334 名女性（36%）。在 2013 年至 2017 年期间，向 162 名外科肿瘤学家支付了总计 4659.6706 万美元的研究款项（17.5%）：用于与药物和临床试验相关的研究的款项为 4077.4716 万美元（87%），而用于外科设备的款项为 519.4199 万美元（11%）（p=0.018）。资金与学术领导地位和从业年限相关（p=0.0001 和 p=0.0037）。马萨诸塞州（906.0976 万美元）、德克萨斯州（765.6228 万美元）和纽约州（421.0864 万美元）获得的资金最多，而犹他州（153.3166 美元/外科医生）、马萨诸塞州（129.4425 美元/外科医生）和俄勒冈州（124.1702 美元/外科医生）获得的平均每外科医生支付金额最高。大多数资金来自诺华公司（1604.5608 万美元）、安进公司（681.0832 万美元）和默克公司（375.8299 万美元），用于一种肿瘤溶解疫苗（替莫唑胺拉帕尼培，5939.007 万美元）、一种 BRAF 抑制剂（达拉非尼，5727.309 万美元）和一种 KIT 抑制剂（伊马替尼，4323.586 万美元）。男性外科肿瘤学家比女性更频繁地获得资金（120/588 [20%] vs. 42/334 [12.6%]；p=0.0027）。男性还获得了更多的一般付款（旅行/住宿、食品/饮料、咨询/演讲费）：分别为 48830 美元和 11867 美元（p=0.0001）。
行业对外科肿瘤学家的大部分研究支付都与新的药物有关，这突出了外科肿瘤学家在系统治疗中发挥的作用不断扩大。行业支付受地点、性别和学术领导地位的影响。
